Syros Pharmaceuticals Inc (SYRS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Nancy A. Simonian
Employees:
120
620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE, MA 02139
617-744-1340

Syros Pharmaceuticals, Inc. focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome.

Data derived from most recent annual or quarterly report
Market Cap 23.312 Million Shares Outstanding6.301 Million Avg 30-day Volume 88.979 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.35
Price to Revenue6.0111 Debt to Equity0.5722 EBITDA-89.588 Million
Price to Book Value0.6964 Operating Margin-1151.7102 Enterprise Value-30.385 Million
Current Ratio7.373 EPS Growth0.783 Quick Ratio7.115
1 Yr BETA 0.9931 52-week High/Low 11.5 / 2.42 Profit Margin-754.4028
Operating Cash Flow Growth-20.8075 Altman Z-Score-4.07 Free Cash Flow to Firm -111.434 Million
Earnings Report2023-08-09
View SEC Filings from SYRS instead.

View recent insider trading info

Funds Holding SYRS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SYRS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-06-02:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-25:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2022-12-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-12-12:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2022-12-01:
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-06:
    Item 8.01: Other Events
  • 8-K: filed on 2022-09-16:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proposed Sales (Form 144)

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WIRTH PETER

    • Director
    12,000 2023-06-01 2

    TYSON TIMOTHY

    • Director
    29,189 2023-06-01 5

    AKKARAJU SRINIVAS

    • Director
    0 2023-06-01 3

    FANUCCI MARSHA

    • Director
    12,000 2023-06-01 2

    DUNSIRE DEBORAH

    • Director
    0 2023-06-01 2

    YOUNG RICHARD A

    • Director
    36,171 2023-06-01 2

    ALLES MARK J

    • Director
    0 2023-06-01 2

    OH ANDREW M.

    • Director
    12,000 2023-06-01 3

    ECKHARDT SUE GAIL

    • Director
    12,000 2023-06-01 2

    SIMONIAN NANCY A PRESIDENT & CEO

    • Officer
    • Director
    73,420 2023-03-31 3

    ROTH DAVID CHIEF MEDICAL OFFICER

    • Officer
    7,348 2023-03-31 3

    OLSON ERIC R CHIEF SCIENTIFIC OFFICER

    • Officer
    7,350 2023-03-31 3

    STEPHENS KRISTIN CHIEF DEVELOPMENT OFFICER

    • Officer
    4,465 2023-03-31 3

    CHEE CONLEY CHIEF COMMERCIAL OFFICER

    • Officer
    1,342 2023-03-31 4

    HAAS JASON CHIEF FINANCIAL OFFICER

    • Officer
    1,377 2023-03-31 3

    QUIRK GERALD E CHIEF LEGAL OFFICER

    • Officer
    45,000 2022-10-11 2

    SHARP PHILLIP A

    • Director
    17,500 2022-06-01 0

    NASHAT AMIR

    • Director
    17,500 2022-06-01 0

    SPRINGHORN JEREMY P. CHIEF BUSINESS OFFICER

    • Officer
    0 2021-02-17 0

    FERRA JOSEPH J JR CHIEF FINANCIAL OFFICER

    • Officer
    0 2021-02-17 0

    ARCH VENTURE FUND VII, L.P.

    ARCH VENTURE PARTNERS VII, L.P.

    ARCH VENTURE PARTNERS VII, LLC

    CRANDELL KEITH

    BYBEE CLINTON

    NELSEN ROBERT

    • 10% Owner
    No longer subject to file 2019-07-15 0

    SATO VICKI L

    • Director
    0 2019-06-11 0

    BONNEY MICHAEL W

    • Director
    0 2019-06-11 0

    SHAW ALICE TSANG

    • Director
    0 2019-06-11 0

    AFEYAN NOUBAR

    • 10% Owner
    0 2017-12-31 0

    DESIMONE COLLEEN ELIZABETH PRINCIPAL ACCOUNTING OFFICER

    • Officer
    0 2017-10-23 0

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES FUND IV-RX, L.P.

    FLAGSHIP VENTURELABS IV, LLC

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    AFEYAN NOUBAR

    KANIA EDWIN M JR

    • 10% Owner
    3,253,491 2017-08-17 0

    NELSEN ROBERT

    • Director
    • 10% Owner
    0 2017-06-08 0

    PATEL SANJ K

    • Director
    0 2017-06-08 0

    KUVALANKA KYLE D. CHIEF OPERATING OFFICER

    • Officer
    0 2017-02-10 0

    BANCEL STEPHANE

    • Director
    0 2016-09-15 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • 10% Owner
    • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
    2,095,220 2016-07-06 0

    AISLING CAPITAL III LP

    AISLING CAPITAL PARTNERS III LP

    AISLING CAPITAL PARTNERS III LLC

    ELMS STEVE

    SCHIFF ANDREW N

    PURCELL DENNIS J

    • 10% Owner
    No longer subject to file 2016-07-06 0

    ARCH VENTURE FUND VII LP

    ARCH VENTURE PARTNERS VII, L.P.

    ARCH VENTURE PARTNERS VII, LLC

    CRANDELL KEITH

    BYBEE CLINTON

    • 10% Owner
    4,637,137 2016-07-06 0

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    No longer subject to file 2016-07-06 0

    POLARIS MANAGEMENT CO. VII, L.L.C.

    POLARIS PARTNERS VII, L.P.

    POLARIS ENTREPRENEURS' FUND VII, L.P.

    • 10% Owner
    No longer subject to file 2016-07-06 0

    WUXI HEALTHCARE VENTURES II, L.P.

    • 10% Owner
    No longer subject to file 2016-07-06 0

    WUXI PHARMTECH HEALTHCARE FUND I L.P.

    • 10% Owner
    No longer subject to file 2016-07-06 0

    GRAY NATHANAEL

    • 10% Owner
    426,666 2016-06-29 0

    CONDE JORGE CHIEF STRATEGY OFFICER

    • Officer
    0 2016-06-29 0

    JEB SYROS TRUST

    • 10% Owner
    351,666 2016-06-29 0

    PERSPECTA TRUST LLC

    • 10% Owner
    351,666 2016-06-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    AKKARAJU SRINIVAS - Director

    2023-06-02 16:22:24 -0400 2023-06-01 A 6,000 a 6,000 direct

    TYSON TIMOTHY - Director

    2023-06-02 16:26:13 -0400 2023-06-01 A 6,000 a 6,000 direct

    TYSON TIMOTHY - Director

    2023-06-02 16:26:13 -0400 2023-06-01 A 4,000 a 29,189 direct

    OH ANDREW M. - Director

    2023-06-02 16:25:36 -0400 2023-06-01 A 6,000 a 6,000 direct

    OH ANDREW M. - Director

    2023-06-02 16:25:36 -0400 2023-06-01 A 4,000 a 12,000 direct

    WIRTH PETER - Director

    2023-06-02 16:26:57 -0400 2023-06-01 A 6,000 a 6,000 direct

    WIRTH PETER - Director

    2023-06-02 16:26:57 -0400 2023-06-01 A 4,000 a 12,000 direct

    YOUNG RICHARD A - Director

    2023-06-02 16:27:26 -0400 2023-06-01 A 6,000 a 6,000 direct

    YOUNG RICHARD A - Director

    2023-06-02 16:27:26 -0400 2023-06-01 A 4,000 a 36,171 direct

    FANUCCI MARSHA - Director

    2023-06-02 16:24:58 -0400 2023-06-01 A 4,000 a 12,000 direct

    AKKARAJU SRINIVAS - Director

    2023-06-02 16:22:24 -0400 2023-06-01 A 4,000 a 4,000 direct

    ALLES MARK J - Director

    2023-06-02 16:22:54 -0400 2023-06-01 A 6,000 a 6,000 direct

    ALLES MARK J - Director

    2023-06-02 16:22:54 -0400 2023-06-01 A 4,000 a 4,000 direct

    DUNSIRE DEBORAH - Director

    2023-06-02 16:23:39 -0400 2023-06-01 A 6,000 a 6,000 direct

    DUNSIRE DEBORAH - Director

    2023-06-02 16:23:39 -0400 2023-06-01 A 4,000 a 4,000 direct

    ECKHARDT SUE GAIL - Director

    2023-06-02 16:24:22 -0400 2023-06-01 A 6,000 a 6,000 direct

    ECKHARDT SUE GAIL - Director

    2023-06-02 16:24:22 -0400 2023-06-01 A 4,000 a 12,000 direct

    FANUCCI MARSHA - Director

    2023-06-02 16:24:58 -0400 2023-06-01 A 6,000 a 6,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 22:15:03 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 21:45:05 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 21:15:04 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 20:45:04 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 20:15:04 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 19:45:04 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 19:15:03 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 18:45:04 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 18:15:04 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 17:45:04 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 17:15:04 UTC -5.7385 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 16:45:04 UTC -5.7485 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 16:15:03 UTC -5.7485 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 15:45:04 UTC -5.7485 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 15:15:04 UTC -5.7485 10.8085 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 14:45:04 UTC -7.3585 12.4185 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 14:15:03 UTC -7.3585 12.4185 95000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 13:45:03 UTC -7.3585 12.4185 90000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 13:15:03 UTC -7.3585 12.4185 90000
    SYROS PHARMACEUTICALS INC SYRS 2023-06-06 12:45:05 UTC -7.3585 12.4185 90000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments